The prognostic nutritional index predicts prognosis after liver resection in elderly patients with early-stage hepatocellular carcinoma

Author:

Hu YaFei1,Ma Wen-Jie1,Gu Han-Fei1,Hu Hai-Jie1,Wang Jun-Ke1,Liu Fei1,Lv Tian-Run1,Yang SiQi1,Dai Yu-Shi1,Zou Rui-Qi1,Li Fu-Yu1

Affiliation:

1. Sichuan University

Abstract

Abstract Aims We aimed to determine the value of the preoperative prognostic nutritional index (PNI) and establish new nomograms to predict recurrence-free and overall survival (RFS and OS) in elderly patients with early-stage hepatocellular carcinoma (HCC). Methods Elderly patients (≥ 60 years of age) with very early-stage HCC (CNLC IA-IIA) after curative surgical resection were identified. PNI was calculated by [10 × serum albumin level (gr/dL)] + [0.005 × total lymphocyte count (per mm3)]. Univariate and multivariate Cox analysis was used to screen the variables and construct the nomogram model. ROC and calibration curves were used for model evaluation. Results The PNI-high was defined as ≥ 49.5 and ≥ 49.05 for RFS and OS, respectively. The 5-year-RFS rate was 34.1% in the PNI-low group versus 57.4% in the PNI-high group (P = 0.014). The 5-year OS rate in the PNI-low group was significantly lower than that in the PNI-high groups (68.2% vs. 84.4%, P = 0.033). The nomogram prediction models for patients’ RFS and OS were built by incorporating the same three independent survival predictors, including PNI-low, tumor presence of vascular invasion, and low differentiation. These two prediction models demonstrated good calibration and discrimination, with all C‑indexes greater than 0.72. The calibration plots basically coincide with the diagonal, indicating that the observed RFS and OS were close to the predicted outcomes. Conclusions The PNI-low, tumor presence of vascular invasion, and low differentiation can be adopted as a decision aid to predict the long-term RFS and OS for elderly patients with resected HCC.

Publisher

Research Square Platform LLC

Reference31 articles.

1. Epigenetics in hepatocellular carcinoma;Nagaraju GP;Semin Cancer Biol,2022

2. Hepatocellular carcinoma;Forner A;Lancet,2018

3. Liver cancer stem cell markers: Progression and therapeutic implications;Sun JH;World J Gastroenterol,2016

4. Tumor-associated macrophages in liver cancer: From mechanisms to therapy;Cheng K;Cancer Commun (Lond),2022

5. Changing epidemiology of hepatocellular carcinoma in Asia;Zhang Ch;Liver International,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3